MOUNTAIN VIEW, Calif.,
July 17, 2014 /PRNewswire/
-- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report
results for its fiscal quarter ended June
30, 2014 on Thursday, August 7,
2014, following the close of the U.S. financial markets. The
Company will also host an investor conference call and live webcast
on the same day at 5:00 p.m. Eastern
Time / 2:00 p.m. Pacific Time
to provide a company update and discuss the financial
results.
To access the webcast via the Internet, go to www.alexza.com,
under the "Investor Relations" link. Please log onto the
webcast prior to the start of the call to ensure time for any
software downloads that may be required to participate in the
webcast.
LIVE CALL:
888-713-4213 or +1-617-213-4865
(international)
Passcode: 23868261
Interested parties may also pre-register for the call at:
https://www.theconferencingservice.com/prereg/key.process?key=P7KJF9AQ7
REPLAY:
888-286-8010 or +1-617-801-6888
(international)
Passcode: 24951818
A replay of the conference call may also be accessed at
www.alexza.com under the "Investor Relations" link. A replay
of the call will be available for 14 days following the event.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products are based on the Staccato® system, a hand-held
inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.
ADASUVE® is Alexza's first commercial product and it
has been approved for sale by the U.S. Food and Drug Administration
and the European Commission. Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for
ADASUVE in the U.S. Grupo Ferrer Internacional S.A. is
Alexza's commercial partner for ADASUVE in Europe, Latin
America and the Commonwealth of Independent States
countries.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated news release
and conference call will contain forward-looking statements
that involve significant risks and uncertainties. Any
statement describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of
Alexza and its partners, Teva and Ferrer, to effectively and
profitably commercialize ADASUVE, estimated product revenues
and royalties associated with the sale of ADASUVE, the adequacy of
the Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2013 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo -
http://http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
SOURCE Alexza Pharmaceuticals, Inc.